ALung Technologies, Inc. announced that it has now treated more than 75 COVID-19 patients, and that it is experiencing increasing demand for the Hemolung RAS as a result of the current pandemic.
ALung Technologies Reports FDA Granted the Company Emergency Use Authorization Designation to the Hemolung® Respiratory Assist System for RX of COVID-19
Hemolung® RAS is currently being used in the FDA approved VENT-AVOID trial for the study of ECCO2R in the treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AE-COPD).
12/10/18: Achieves major milestones in its clinical trial programs. In the USA, nearly 30 hospitals are online for ALung’s VENT-AVOID Trial of the Hemolung Respiratory Assist System.
April 25, 2017 ALung Technologies, Inc., announced today the submission of its Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking approval to conduct a pivotal clinical study of the Hemolung Respiratory Assist...